Stock Market Reviews

JAZZ (Jazz Pharmaceuticals plc) News

Get the latest news, insights, and market updates on JAZZ (Jazz Pharmaceuticals plc). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Why Jazz (JAZZ) International Revenue Trends Deserve Your Attention
  Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
  Nov 17, 2025 - $JAZZ
• Why Is Jazz Pharmaceuticals (JAZZ) Stock Soaring Today
  Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 18.3% in the morning session after the company announced positive top-line results from its Phase 3 HERIZON-GEA-01 trial for its cancer drug, Ziihera.
  Nov 17, 2025 - $JAZZ
• Stocks to Watch Recap: Alphabet, Tesla, Netflix, Zymeworks
  ↘️ Netflix (NFLX): The streaming company approved a 10-for-one stock split last month. Trading began on a split-adjusted basis today. Shares fell 0.8%. ↗️ Alphabet (GOOG, GOOGL): Warren Buffett’s Berkshire Hathaway (BRK.
  Nov 17, 2025 - $JAZZ
• Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.
  The companies’ drug Ziihera shows clinically meaningful benefits for patients with gastroesophageal adenocarcinoma.
  Nov 17, 2025 - $JAZZ
• Stocks to Watch Monday: Alphabet, XPeng, Zymeworks
  ↗️ Alphabet (GOOG, GOOGL): Warren Buffett’s Berkshire Hathaway (BRK.A, BRK.B) added Google's parent company to its portfolio last quarter and further shrunk its stake in Apple (AAPL). Alphabet shares jumped more than 4% in premarket trading, while shares in the iPhone maker edged lower.
  Nov 17, 2025 - $JAZZ
• Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer
  Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday after the duo unveiled positive test results for a gastric cancer drug.
  Nov 17, 2025 - $JAZZ
• Is Jazz Pharmaceuticals a Hidden Opportunity After 14% Climb and Expansion in 2025?
  Wondering if Jazz Pharmaceuticals might be a hidden bargain or riding too high? Let’s take a closer look at what investors should know about its current value. The stock has climbed 7.6% in the past week and is up 14.0% year-to-date. This hints at renewed optimism or shifting risk perceptions among investors. Recent headlines highlight Jazz’s ongoing expansion in approved therapies and its strategic moves in the rare disease space. Both factors are contributing to increased attention and...
  Nov 16, 2025 - $JAZZ
• The Top 5 Analyst Questions From Jazz Pharmaceuticals’s Q3 Earnings Call
  Jazz Pharmaceuticals delivered a quarter that exceeded Wall Street’s expectations, with management attributing results to robust demand for Xywav and Epidiolex, as well as the swift and successful launch of Modeyso following its FDA approval. CEO Renée Galá highlighted the company’s execution, noting, "We delivered 2 FDA approvals that underscore Jazz's ability to bring highly differentiated therapies to patients with serious unmet needs." The quarter also saw positive developments in Jazz’s sle
  Nov 12, 2025 - $JAZZ
• Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know
  A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
  Nov 11, 2025 - $JAZZ
• Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will present five abstracts at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting taking place November 19-23 in Honolulu, Hawaii. The presentations will feature both clinical and preclinical research evaluating Modeyso™ (dordaviprone), as well as new preclinical data featuring JZP3507 (formerly ONC206) in central nervous system (CNS) tumors, reflecting Jazz's growing impact and innovation in neuro-oncology.
  Nov 11, 2025 - $JAZZ